Skip to main content

Advertisement

Table 2 Percentage change from baseline in lipid variables at 16 weeks (ITT population). Doses were titrated from week 4 to week 16 in patients who had not reached the 1998 European LDL-C goal (< 3.0 mmol/L)

From: Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study

Variable Least-squares mean percentage change from baseline to 16 weeks Difference (95% CI) p-value
Rosuvastatin 10–40 mg (n = 221) Atorvastatin 10–80 mg (n = 220)
LDL-C -52.3 -45.5 -6.7 (-8.8, -4.7) < 0.0001
TC -35.4 -31.3 -4.1 (-5.8, -2.4) < 0.0001
HDL-C 5.3 4.0 1.3 (-1.3, 3.8) NS
TG -21.2 -21.1 -0.1 (-5.6, 5.3) NS
Non-HDL-C -45.0 -39.6 -5.5 (-7.4, -3.5) < 0.0001
LDL-C/HDL-C ratio -54.1 -47.0 -7.1 (-9.3, -4.9) < 0.0001
Non-HDL-C/HDL-C ratio -47.1 -40.9 -6.2 (-8.6, -3.9) < 0.0001
TC/HDL-C ratio -38.0 -33.1 -5.0 (-6.9, -3.0) < 0.0001
Apo B -45.2 -40.1 -5.1 (-7.2, -3.1) < 0.0001
Apo A-I 2.6 -0.2 2.8 (1.0, 4.6) 0.0024
Apo B/apo A-I ratio -46.3 -39.6 -6.7 (-8.9, -4.6) < 0.0001
  1. ITT: Intention to treat, CI: Confidence interval, LDL-C: Low-density lipoprotein cholesterol, TC: Total cholesterol, HDL-C: High-density lipoprotein cholesterol, TG: Triglycerides, Apo: Apolipoprotein, NS: Not statistically significant